Vilon

Origin and Structure

Vilon is a synthetic dipeptide with the sequence Lys-Glu (lysyl-glutamic acid), developed by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology. It is part of the Khavinson school's program of "short peptide bioregulators" — ultrashort peptides (typically 2–4 residues) derived or inspired by organ-specific tissue extracts, designed to penetrate cell nuclei and modulate gene expression in targeted tissues. Vilon was developed specifically as a thymic/immune bioregulator, the synthetic follow-up to the organ-extract compound Thymalin.

Mechanism of Action

The proposed mechanism, as articulated in Khavinson's peer-reviewed papers and monographs, is that the dipeptide enters cells, translocates to the nucleus, and interacts directly with DNA — preferentially binding CpG-rich regions of promoters for immune-relevant genes. This interaction is proposed to modulate expression of thymic differentiation markers, restore age-related decline in T-cell subpopulations, and normalize NK cell activity. The mechanism is explicitly epigenetic/gene-regulatory rather than receptor-mediated, which is a significant departure from conventional peptide pharmacology and is one reason the Khavinson model has not been fully adopted in Western molecular biology.

Clinical Evidence

The Vilon evidence base is almost entirely Russian. Published studies, many in the journal Bulletin of Experimental Biology and Medicine and in Khavinson's own monographs, report:

• Restoration of T-cell subsets in older adults. Multiple small clinical series have described improvements in CD4/CD8 ratios, lymphocyte proliferative response to mitogens, and NK activity after 10-day Vilon courses in patients aged 60 and older.
• Adjunct use in oncology and radiation exposure. Reports from Chernobyl-cohort studies and post-chemotherapy populations describe faster immune recovery, though trial methodology varies.
• Lifespan extension in rodents. Anisimov and Khavinson have reported modest extensions of mean and maximal lifespan in female mice given Vilon, alongside reductions in spontaneous tumor incidence.

These findings are internally consistent within the Khavinson literature but have attracted very limited independent replication in Western journals. Most reviews outside the Russian literature characterize the data as provocative but not yet definitive.

Honest Evidence Assessment

Vilon illustrates the recurring challenge with Khavinson short peptides: a substantial body of clinical and preclinical work published over 25 years, conducted by a cohesive research school with consistent methodology, but with almost no contact with Western randomized trial infrastructure. For readers accustomed to ICH-GCP Phase 3 evidence, the Vilon file feels thin; for readers familiar with Russian clinical pharmacology traditions, the cumulative case is more substantial. Both readings are defensible.

Practical Considerations

In Russian clinical practice, Vilon has been administered intramuscularly at 100–200 mcg/day in 10-day courses, typically repeated every 4–6 months. Oral encapsulated formulations exist. Research-chemical suppliers outside Russia also offer subcutaneous injection formats at similar doses, though no regulatory body in Western markets has reviewed these.

Safety and Regulatory Status

Russian clinical literature reports an essentially clean safety profile — no significant adverse events attributable to the peptide across decades of use. Vilon is registered in Russia and several CIS states as a bioregulator. It has no FDA, EMA, MHRA, or TGA approval, and is not available through pharmacies in those jurisdictions. Western supply is entirely via research-chemical channels, with the identity and purity concerns that entails for a short dipeptide that is difficult to distinguish analytically from inert material without proper mass spectrometry.

Bottom Line

Vilon is the canonical Khavinson immune-system bioregulator, with a respectable Russian clinical footprint and a near-absent Western evidence base. Readers should treat it as an interesting hypothesis with unconventional mechanistic claims, not as a validated immunomodulator. For a broader view of the Khavinson program, see epithalon, the best-known member of the family, and our biological age article for context on aging-biomarker interventions.